-transparent.png){kind=logo}
Nine patients with acute myelogenous leukaemia were treated with low-dose ARA-C (10 mg/m2, q 12h) for a planned 21 d. Complete remission was attained in only one patient (11.1%). Definite cytoreductive effect was seen in four additional patients. There was one treatment-related death. Haematologic toxicity occurred in all nine patients with sever thrombocytopenia most prominent. Severe hepatotoxicity precluded further ARA-C treatment in one patient. Because of toxicity only two patients were able to complete their scheduled 3 week courses of low-dose ARA-C. No evidence of ARA-C induced differentiation of leukaemic cells was noted on follow-up bone marrow examination during or shortly after the treatment course. The utility and indication for low-dose ARA-C therapy of AML remains to be determined.
R T Perri, and
D J Weisdorf, and
M M Oken
April 1986,
British journal of haematology,
R T Perri, and
D J Weisdorf, and
M M Oken
January 1988,
Medical oncology and tumor pharmacotherapy,
R T Perri, and
D J Weisdorf, and
M M Oken
December 1990,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
R T Perri, and
D J Weisdorf, and
M M Oken
December 2021,
Blood advances,
R T Perri, and
D J Weisdorf, and
M M Oken
April 1984,
Blut,
R T Perri, and
D J Weisdorf, and
M M Oken
March 1987,
British journal of haematology,
R T Perri, and
D J Weisdorf, and
M M Oken
July 1983,
Blood,
R T Perri, and
D J Weisdorf, and
M M Oken
January 1986,
Leukemia research,
R T Perri, and
D J Weisdorf, and
M M Oken
June 1985,
Seminars in oncology,
